You're watching:
S3 E26 - Unlocking Success for Biotech Startups with a 95% Success Rate
Interview with David Kiewlich
Tomorrow Biotech Corporation consists of an accelerator fund, an early stage fund and includes the Bay Area Disruptor and Startup Support Labs (BADASS Labs) a 501c3, non-profit series of biotech incubators. While the funds are new, the incubator has been in operation for 6 years, supporting dozens of pre-seed through series B (and beyond) companies. With a track record of 50 of 55 company successes for members of the incubator, this ecosystem has a uniquely successful approach to founder support, which has substantially changed the concept and expectations for early stage incubators.
BADASS Labs is more than a 501c3, non-profit biotech incubator that rents lab space to small businesses. It is a strategic ally that empowers biotech entrepreneurs to achieve their full potential. By offering a comprehensive suite of services, such as purchasing, waste management, operations and even health insurance plans for its members, BADASS Labs enables its clients to focus on their core competencies and substantially reduce their operational costs. BADASS Labs bridges the gap between research and commercialization, by facilitating novel technologies from academic, national lab or self-generated sources into viable products that can enhance the domestic supply chain and generate regional employment. While we can incubate companies at any stage, we have a particular focus on the earlier side, from Pre-Seed through Series B stages.
Dr. David Kiewlich (Ph.D. in Cell and Developmental Biology) is a serial founder and entrepreneur in biotech. With over 35 years’ experience working for industry, as well as 6 startups of his own (in Oncology, Cell Based Therapies and Synthetic Biology), his background is excellently aligned with the needs and struggles of pre-commercialization startups. He founded and runs Tomorrow Biotech, which includes the Bay Area Disruptor and Startup Support Labs (BADASS Labs) a 501c3, non-profit series of biotech incubators, which has supported dozens of pre-seed through series B (and beyond) companies, as well as a startup and early-stage fund.
In addition to Tomorrow Biotech, David is also the CSO of a cell based therapy company, focused on autoimmune disease, advisor for several biotech startups and frequent public speaker advocating for increased sustainability and greater Diversity, Equity and Inclusion (DEI) in the sciences.
